BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT) have received a consensus rating of “Moderate Buy” from the six analysts that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $24.25.

Several research firms have issued reports on BBOT. Wall Street Zen cut shares of BridgeBio Oncology Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 16th. HC Wainwright upped their price target on shares of BridgeBio Oncology Therapeutics from $27.00 to $29.00 and gave the company a “buy” rating in a research report on Friday, March 6th. Canaccord Genuity Group assumed coverage on shares of BridgeBio Oncology Therapeutics in a research report on Monday, May 11th. They set a “buy” rating and a $23.00 price target for the company. Oppenheimer assumed coverage on shares of BridgeBio Oncology Therapeutics in a research report on Monday, June 22nd. They set an “outperform” rating and a $22.00 price target for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BridgeBio Oncology Therapeutics in a research report on Thursday, June 18th.

Institutional Investors Weigh In On BridgeBio Oncology Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. CIBC Private Wealth Group LLC purchased a new stake in shares of BridgeBio Oncology Therapeutics during the 4th quarter valued at about $63,000. Persistent Asset Partners Ltd purchased a new stake in shares of BridgeBio Oncology Therapeutics during the 4th quarter valued at about $107,000. Squarepoint Ops LLC purchased a new stake in shares of BridgeBio Oncology Therapeutics during the 4th quarter valued at about $144,000. Quadrature Capital Ltd purchased a new stake in shares of BridgeBio Oncology Therapeutics during the 4th quarter valued at about $162,000. Finally, BIT Capital GmbH purchased a new stake in shares of BridgeBio Oncology Therapeutics during the 4th quarter valued at about $313,000. Hedge funds and other institutional investors own 54.89% of the company’s stock.

BridgeBio Oncology Therapeutics Stock Up 3.5%

BBOT opened at $7.66 on Tuesday. The company has a market cap of $613.62 million, a PE ratio of -3.74 and a beta of 0.29. The company’s 50-day moving average is $8.23. BridgeBio Oncology Therapeutics has a 52-week low of $7.00 and a 52-week high of $14.87.

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) last posted its earnings results on Tuesday, May 12th. The company reported ($526.11) earnings per share (EPS) for the quarter. Research analysts forecast that BridgeBio Oncology Therapeutics will post -2.33 earnings per share for the current fiscal year.

BridgeBio Oncology Therapeutics Company Profile

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need.

BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development.

Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here.